

Special Issue

(Virus-Like) Particles as Platforms for Vaccine Delivery and Modulation of Immune Cell Function

Message from the Guest Editor

Our immune system preferentially discriminates between self and non-self antigens, thus contributing to long-term homeostasis. Some antigens are introduced in a (water-)soluble form into our body. In contrast, other antigens are part of a smaller or larger particulate context, such as virus particles, bacteria, or even larger microorganisms. On the one hand, it may be interesting to induce potent effector and memory functions. In contrast, on the other hand, immune responses may be directed towards regulatory responses. Since the (virus-like) particles themselves can be varied not only in size and physicochemical composition but also in the way they express nominal antigens and transport them to the host organisms, they are ideally suited for the delivery of vaccine antigens and as platforms for triggering immunoregulatory responses. We encourage all scientists interested in research based on (virus-like) particles and immunomodulation to submit their manuscripts for this Special Issue of *Vaccines* and guarantee expert and timely peer review.

Guest Editor

Dr. Winfried F. Pickl

Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Lazarettgasse 19, 1090 Vienna, Austria

Deadline for manuscript submissions

31 May 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/208105

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).